ECCO 2018: Novel treatments in IBD
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
by Maria Dalby Effective treatment options for perianal fistulas constitute a major unmet need in Crohn’sdisease (CD). New interventions included a knot-free silicon drain to replace conventional setons, and a circular blade… read more.
ESCP 2017 delegates give their highlights, plus a report on the ESCP/ECCO symposium on ulcerative colitis and a focus on quality of life for patients with perianal Crohn’s disease.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a… read more.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) In an overview of the immunological rationale for, and clinical application of adipose-derived mesenchymal stem cell (MSC) therapies, Dr… read more.
Dr Peter Irving (London) talks about one of the hot topics for the future -Maximising the bang for your buck in IBD. He highlights the possible benefits of treating… read more.
An interesting session at ECCO dealt with the patients for whom there is sparce data to guide their treatment – experts in the field gave their guidance to… read more.
Never before in the history of IBD have there been so many promising compounds in the pipeline. In a scientific session dedicated to new compounds, leading investigators discussed… read more.
Dr Filip Baert (Roeselare, Belgium) gives a summary of his session on trial endpoints vs therapeutic objectives. he also discusses the role of ECCO in improving the data generated in… read more.
by Gary Finnegan: People seeking refuge and asylum in Germany are at higher risks of liver problems due to hepatitis B, according to experts.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Biomarkers emerging as guide on immunosuppression by Thomas R. Collins Using the right amount of immunosuppression treatment, but no more than necessary, is a challenge facing clinicians handling… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.